Table 1 Characteristics of the patients at inclusion
From: Aldolase predicts subsequent myopathy occurrence in systemic sclerosis
Patients with systemic sclerosis (n= 137) | |
|---|---|
Age (years) | 54.8 ± 12.9 |
Female, n (%) | 125 (91.2) |
Duration of SSc disease (years) | 12.2 ± 12.0 |
Diffuse, n (%) | 42 (31) |
Modified Rodnan skin score | 8.1 ± 6.0 |
Myalgia, n (%) | 77 (56) |
DLCO (% pred) | 64 ± 17 |
ILD, n (%) | 51 (37.1) |
ATA, n (%) | 37 (27) |
ACA, n (%) | 62 (45) |
Anti U1-RNP antibody | 8 (5.8) |
Anti U3-RNP antibody | 6 (4.3) |
Anti PM-Scl antibody | 5 (3.6) |
Anti RNA polymerase III antibody | 4 (2.9) |
C-reactive protein (mg/L) | 5.2 ± 7.6 |
Plasma aspartate transaminases (0 to 32 U/L) | 23.1 ± 9.3 |
Plasma alanine transaminases (0 to 32 U/L) | 21.5 ± 14.0 |
Plasma aldolase (0 to 7 U/L) | 10.3 ± 7.5 |
Plasma creatine kinase (0 to 160 U/L) | 111.1 ± 142.1 |
Immunosuppressive treatment, n (%) | 18 (13) |